Van Slyke Greta, Angalakurthi Siva Krishna, Toth Ronald T, Vance David J, Rong Yinghui, Ehrbar Dylan, Shi Yuqi, Middaugh C Russell, Volkin David B, Weis David D, Mantis Nicholas J
Division of Infectious Diseases, Wadsworth Center, New York State Department of Health, Albany, NY 12208.
Macromolecule and Vaccine Stabilization Center, Department of Pharmaceutical Chemistry, University of Kansas, Lawrence, KS 66045.
Immunohorizons. 2018 Sep;2(8):262-273. doi: 10.4049/immunohorizons.1800042.
Ricin is a fast-acting protein toxin classified by the Centers for Disease Control and Prevention as a biothreat agent. In this report, we describe five new mouse mAbs directed against an immunodominant region, so-called epitope cluster II, on the surface of ricin's ribosome-inactivating enzymatic subunit A (RTA). The five mAbs were tested alongside four previously described cluster II-specific mAbs for their capacity to passively protect mice against 10× LD ricin challenge by injection. Only three of the mAbs (LE4, PH12, and TB12) afforded protection over the 7-d study period. Neither binding affinity nor in vitro toxin-neutralizing activity could fully account for LE4, PH12, and TB12's potent in vivo activity relative to the other six mAbs. However, epitope mapping studies by hydrogen exchange-mass spectrometry revealed that LE4, PH12, and TB12 shared common contact points on RTA corresponding to RTA α-helices D and E and β-strands and e located on the back side of RTA relative to the active site. The other six mAbs recognized overlapping epitopes on RTA, but none shared the same hydrogen exchange-mass spectrometry profile as LE4, PH12, and TB12. A high-density competition ELISA with a panel of ricin-specific, single-domain camelid Abs indicated that even though LE4, PH12, and TB12 make contact with similar secondary motifs, they likely approach RTA from different angles. These results underscore how subtle differences in epitope specificity can significantly impact Ab functionality in vivo. , 2018, 2: 262-273.
蓖麻毒素是一种作用迅速的蛋白质毒素,被美国疾病控制与预防中心列为生物威胁制剂。在本报告中,我们描述了五种针对蓖麻毒素核糖体失活酶亚基A(RTA)表面免疫显性区域(即所谓的表位簇II)的新型小鼠单克隆抗体。将这五种单克隆抗体与之前描述的四种簇II特异性单克隆抗体一起进行测试,以评估它们通过注射被动保护小鼠免受10倍致死剂量蓖麻毒素攻击的能力。在为期7天的研究期间,只有三种单克隆抗体(LE4、PH12和TB12)提供了保护。相对于其他六种单克隆抗体,结合亲和力和体外毒素中和活性都不能完全解释LE4、PH12和TB12强大的体内活性。然而,通过氢交换质谱进行的表位作图研究表明,LE4、PH12和TB12在RTA上具有共同的接触点,对应于RTA的α螺旋D和E以及位于RTA相对于活性位点背面的β链 和e。其他六种单克隆抗体识别RTA上重叠的表位,但没有一种与LE4、PH12和TB12具有相同的氢交换质谱图谱。一项使用一组蓖麻毒素特异性单域骆驼科抗体的高密度竞争ELISA表明,尽管LE4、PH12和TB12与相似的二级基序接触,但它们可能从不同角度接近RTA。这些结果强调了表位特异性的细微差异如何能显著影响抗体在体内的功能。, 2018, 2: 262 - 273。